News | July 19, 2011

German Patient Surpasses 5 Years of Support on DuraHeart Left Ventricular Assist Device

July 19, 2011 — Terumo Heart Inc., a wholly owned subsidiary of Terumo Corp., announced that a patient implanted with the DuraHeart left ventricular assist system (LVAS) has surpassed five years of support on the mechanical circulatory support device. Helga Gieseke, living in Germany, was treated at The Deutsches Herzzentrum Berlin (DHZB, German Heart Institute Berlin) and is now one of the longest-living heart failure recipients of the DuraHeart LVAS device.

"Now I can breathe again,” she said. “For years before I received the DuraHeart I was unable to do anything with my children or grandchildren. Since the DuraHeart, I was able to experience the birth of my little grandchild. I can now do things like walk and play catch and am able to participate in the lives of my family."

Gieseke's heart problems have been occurring since the 1980s; her first heart surgery was performed in 1994. Between 1994 and 2006, she underwent several procedures including implantation of stents, pacemakers and implantable defibrillators in an attempt to manage her condition. Despite all these treatments, Mrs. Gieseke's condition continued to deteriorate until she found herself unable to walk or carry out simple activities without experiencing chest pain and being short of breath.

Gieseke admits that without the DuraHeart, she would probably not have lived to see her most recent birthday. "DuraHeart was my only option; there is a shortage of donor organs, and DuraHeart was my last chance. My family supported my decision [to implant an investigational device] and we have all been extremely happy with the decision and the quality of life the DuraHeart has afforded me."

The system is the latest-generation rotary blood pump designed for long-term patient support. The system incorporates a centrifugal flow rotary pump with the magnetically levitated impeller. The pump features three position sensors and electromagnetic coils that suspend the impeller inside the pump chamber without a single contact point. The impeller's active magnetic levitation is designed to eliminate friction by allowing a wide gap between blood contacting surfaces, enabling blood to flow through the pump unimpeded in a smooth, non-turbulent fashion.

The DuraHeart carries a CE mark and is currently available for sale in Japan and Europe. It is limited to investigational use only in the United States.

For more information:

Related Content

Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD) | May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD) | April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD) | April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD) | March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD) | March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
Overlay Init